Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) cytoreductive surgery

women with stage III-IV ovarian cancer, undergoing delayed (\>5 cycles of chemotherapy) cytoreductive surgery

women with stage III-IV ovarian cancer, undergoing \>5 cycles of chemotherapy alone (no cytoreductive surgery)

cytoreductive surgery after 3-4 cycles of chemotherapy

interval cytoreductive surgery

delayed cytoreductive surgery

no cytoreductive surgery (\>5 cycles of chemotherapy alone)

no surgery

Faiza Gaba

To compare patient outcomes following interval and delayed cytoreductive surgeries and no surgery (neoadjuvant chemotherapy alone) and international variations in access to cytoreductive surgeries in women with advanced stage ovarian cancer.

Standard of care in patients with advanced ovarian cancer is primary cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy and interval cytoreductive surgery is an alternative in selected patients. Most data exist with interval cytoreductive surgery following 3-4 cycles of chemotherapy, however, some patients experience a delay. So far, the impact of delayed cytoreductive surgery (following \>5 cycles of chemotherapy) on patient outcomes is poorly defined. There is also a paucity of data in women who undergo no surgery (\>5 cycles of chemotherapy alone) and factors influencing international discrepancies in access to cytoreductive surgery.

Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer

Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer: A GO SOAR Led Study (GO SOAR2)

defined from date of diagnosis to date of death by any cause or loss to follow-up

defined from date of diagnosis to date of first recurrence

topic guide interview questionnaire to be used to elicit factors aiding/preventing access to cytoreductive surgery internationally

R0 = no visible disease, R1 = \<10mm visible residual disease, R2 = \>10mm visible residual disease

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer	NCT05523804	Ovarian Cancer	interval cytore... delayed cytored... no surgery	18 Years -	NHS Grampian
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer	NCT05523804	Ovarian Cancer	interval cytore... delayed cytored... no surgery	18 Years -	NHS Grampian
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer	NCT05523804	Ovarian Cancer	interval cytore... delayed cytored... no surgery	18 Years -	NHS Grampian
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer	NCT05523804	Ovarian Cancer	interval cytore... delayed cytored... no surgery	18 Years -	NHS Grampian

Spots Global Cancer Trial Database for delayed cytoreductive surgery